BioVie’s Bezisterim Improves Fatigue in More Severely Affected Long COVID Patients in Phase 2 Trial

• BioVie presented Phase 2 ADDRESS-LC results for bezisterim in Long COVID at the American Neurological Association annual meeting in San Diego.
• The placebo-controlled trial enrolled 203 patients for 12 weeks; overall results showed a trend toward improvement across most efficacy measures.
• Patients with greater baseline symptom severity showed the strongest benefits, including statistically significant improvements in fatigue, post-exertional malaise or cognition.
• Safety and tolerability were comparable to placebo, with no serious treatment-emergent adverse events in the bezisterim group.
• The findings could guide a confirmatory Phase 3 study; biomarker results remain pending analysis for presentation at a future medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9848011) on October 19, 2026, and is solely responsible for the information contained therein.